KemPharm, Inc. (NASDAQ:KMPH) major shareholder Delaware Street Capital Master bought 325,888 shares of the business’s stock in a transaction on Thursday, September 14th. The shares were acquired at an average price of $3.27 per share, for a total transaction of $1,065,653.76. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

KemPharm, Inc. (KMPH) opened at 3.55 on Friday. KemPharm, Inc. has a 1-year low of $2.45 and a 1-year high of $5.40. The stock has a 50 day moving average price of $3.07 and a 200-day moving average price of $3.80. The stock’s market capitalization is $52.03 million.

KemPharm (NASDAQ:KMPH) last announced its quarterly earnings data on Thursday, August 10th. The specialty pharmaceutical company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.19. Equities research analysts expect that KemPharm, Inc. will post ($2.72) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Delaware Street Capital Master Buys 325,888 Shares of KemPharm, Inc. (KMPH) Stock” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/09/17/delaware-street-capital-master-buys-325888-shares-of-kempharm-inc-kmph-stock.html.

Several analysts have commented on KMPH shares. Roth Capital started coverage on KemPharm in a research note on Wednesday, June 28th. They set a “buy” rating and a $8.00 target price on the stock. ValuEngine upgraded KemPharm from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 1st. Zacks Investment Research upgraded KemPharm from a “sell” rating to a “hold” rating in a research note on Wednesday, July 12th. Canaccord Genuity set a $7.00 target price on KemPharm and gave the company a “buy” rating in a research note on Thursday, August 10th. Finally, Oppenheimer Holdings, Inc. set a $13.00 target price on KemPharm and gave the company a “buy” rating in a research note on Thursday, August 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $8.10.

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its holdings in shares of KemPharm by 17.6% during the first quarter. Bank of New York Mellon Corp now owns 22,854 shares of the specialty pharmaceutical company’s stock valued at $112,000 after buying an additional 3,414 shares during the last quarter. Victory Capital Management Inc. purchased a new stake in shares of KemPharm during the first quarter valued at $647,000. Finally, C WorldWide Group Holding A S grew its holdings in shares of KemPharm by 110.1% during the second quarter. C WorldWide Group Holding A S now owns 381,699 shares of the specialty pharmaceutical company’s stock valued at $1,527,000 after buying an additional 200,000 shares during the last quarter. 40.01% of the stock is currently owned by hedge funds and other institutional investors.

About KemPharm

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Insider Buying and Selling by Quarter for KemPharm (NASDAQ:KMPH)

Receive News & Stock Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related stocks with our FREE daily email newsletter.